目的：探索利用树突状细胞（dendritic cells，DC）制备针对EB病毒感染相关性肿瘤的疫苗，以解决EB病毒相关性肿瘤在机体内的免疫逃逸。方法：来源于正常人骨髓的CD34+造血干/祖细胞，体外以重组hGM-CSF，hTNF-α，hIL-4，hIL-3诱导培养2周，扩增出功能成熟的DC，经EB病毒表面膜糖蛋白gp340刺激，探讨DC诱导T淋巴细胞介导免疫应答的能力，观察负载抗原gp340 DC诱导出的抗原特异性CTL对EB病毒相关性肿瘤细胞的杀伤作用。结果：从人骨髓细胞中诱导扩增出的DC具有良好的免疫刺激活性；EB病毒表面膜糖蛋白gp340可有效负载DC，DC加工处理抗原后激发T淋巴细胞增殖反应的能力进一步增强；在EB病毒相关性肿瘤细胞的杀伤实验中，只有负载了抗原gp340的DC，才能刺激特异性CTL杀伤EB病毒相关性肿瘤细胞。结论：以控制EB病毒感染的疫苗致敏DC，能促进抗原提呈并启动抗肿瘤免疫，体外可有效杀伤EB病毒相关性肿瘤细胞。DC疫苗作为一种针对EB病毒相关性肿瘤的新型治疗性疫苗，会有着良好的研究价值和开发前景。

Objective: Designing dendritic-cell-based vaccines against cancer concerned with the infection of EBV to solve tumor escape. Methods: CD34+ hematopoietic stem cells of bone marrow were cultured in presence of hGM-CSF,hTNF-α,hIL-3,hIL-4 in vitro for two weeks to obtain large amount of DC. DC were characterized by FACS analysis and pulsed with the EBV envelope glycoprotein gp340. The gp340-loaded DC initiate T lymphocytes to induce T lymphocytes activated (CTL) against cancer concerned with the infection of EBV. Results: Marrow-derived DC expressing high levels of CD1а have typical dendritic morphology. They could acquire Epstein-Barr virus latent membrane glycoprotein gp340 efficiently and induce T cells increasing stimulatory capacity in MLR. Only gp340-loaded DC could induce special CTL against tumor cells concerned with the infection of EBV in cytotoxicity assays. Conclusion: Using DC pulsed with EBV vaccines against EBV infection could start up anti-tumor immunity and induce specific CTLs to availability kill tumor cells associated with EBV in vitro.

重庆市院士基金项目（6317）资助